Advanced/metastatic bladder cancer: current status and future directions

被引：37

作者：

Facchini, G. ^{[1
]}

Cavaliere, C. ^{[2
]}

Romis, L. ^{[3
]}

Mordente, S. ^{[3
]}

Facchini, S. ^{[4
]}

Iovane, G. ^{[5
]}

Capasso, M. ^{[5
]}

D'Errico, D. ^{[5
]}

Liguori, C. ^{[1
]}

Formato, R. ^{[1
]}

Cicala, S. ^{[1
]}

Andreozzi, F. ^{[6
]}

Di Lauro, G. ^{[3
]}

Imbimbo, C. ^{[4
]}

Vanni, M. ^{[7
]}

D'Aniello, C. ^{[8
]}

机构：

[1] ASL NA 2 Nord SM delle Grazie Hosp, UOC Med Oncol, Pozzuoli, NA, Italy

[2] ASL NA 3 Sud Osped Riuniti Area Nolana, UOC Med Oncol, Nola, NA, Italy

[3] ASL NA 2 Nord SM delle Grazie Hosp, UOC Urol, Pozzuoli, NA, Italy

[4] Univ Federico II Napoli, Dept Urol, Naples, Italy

[5] IRCCS Fdn G Pascale, Dept Unit Clin & Expt UroAndrol Oncol, Ist Nazl Tumori, Naples, Italy

[6] Univ Naples 2, Med Oncol, Naples, Italy

[7] Hlth Manager ASL NA 2 Nord, Naples, Italy

[8] AORN COLLI Osped Monaldi Cotugno CTO, Div Med Oncol, Naples, Italy

来源：

EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES | 2020年 / 24卷 / 22期

关键词：

Bladder cancer; Chemotherapy; Prognostic factors; Immunotherapy; METASTATIC UROTHELIAL CARCINOMA; TRANSITIONAL-CELL-CARCINOMA; ENDOTHELIAL GROWTH-FACTOR; PHASE-II TRIAL; OPEN-LABEL; FACTOR RECEPTOR; DOUBLE-BLIND; COMPARING GEMCITABINE; 1ST-LINE TREATMENT; 2ND-LINE TREATMENT;

D O I：

10.26355/eurrev_202011_23795

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

In 2015 bladder cancer was the fourth most frequent malignancy and the eighth cause of death for cancer. At diagnosis, about 30% of bladder cancer (BC) patients present a muscle-invasive bladder cancer (MIBC) and 5% a metastatic bladder carcinoma (MBC). For fit MBC patients, combination chemotherapy (CC) is the standard of care for first-line treatment. CC includes both the treatment with methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) either the classical or the dose-dense MVAC regimen, and the doublet therapy with cisplatin and gemcitabine (CG). Median progression free survival (PFS) was 7 months and median overall survival (OS) was 15 months. The present review provides an update on the management of MBC, with focus on target therapies, immune checkpoint inhibition, looking for prognostic and predictive factors.

引用

页码：11536 / 11552

页数：17

共 50 条

[1] Systemic chemotherapy for patients with advanced and metastatic bladder cancer: current status and future directions
Lorusso, Vito
Silvestris, N.
ANNALS OF ONCOLOGY, 2005, 16 : 85 - 89
[2] Current treatment of metastatic bladder cancer and future directions
Lei, Amy Q.
Cheng, Liang
Pan, Chong-xian
EXPERT REVIEW OF ANTICANCER THERAPY, 2011, 11 (12) : 1851 - 1862
[3] Chemotherapy in advanced bladder cancer: current status and future
Ismaili, Nabil
Amzerin, Mounia
Flechon, Aude
JOURNAL OF HEMATOLOGY & ONCOLOGY, 2011, 4
[4] Chemotherapy in advanced bladder cancer: current status and future
Nabil Ismaili
Mounia Amzerin
Aude Flechon
Journal of Hematology & Oncology, 4
[5] Targeted Therapy in Metastatic Bladder Cancer: Present Status and Future Directions
Scholtes, Mathijs
Akbarzadeh, Maryam
Zwarthoff, Ellen
Boormans, Joost
Mahmoudi, Tokameh
Zuiverloon, Tahlita
APPLIED SCIENCES-BASEL, 2020, 10 (20): : 1 - 14
[6] Chemotherapy of advanced ovarian cancer: Current status and future directions
Ozols, RF
Vermorken, JB
SEMINARS IN ONCOLOGY, 1997, 24 (01) : S1 - S9
[7] Antiangiogenic Therapy for Metastatic Breast Cancer Current Status and Future Directions
Chan, Arlene
DRUGS, 2009, 69 (02) : 167 - 181
[8] Current status on the place of FOLFIRINOX in metastatic pancreatic cancer and future directions
Lambert, Aurelien
Gavoille, Celine
Conroy, Thierry
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2017, 10 (08) : 631 - 645
[9] Current status of systemic treatment in locally advanced and metastatic bladder cancer
De Mulder, PHM
RENAL, BLADDER, PROSTATE AND TESTICULAR CANCER: AN UPDATE, 2001, : 281 - 290
[10] Current status and future directions of the use of novel immunotherapeutic agents in bladder cancer
Lenfant, Louis
Aminsharifi, Alireza
Seisen, Thomas
Roupret, Morgan
CURRENT OPINION IN UROLOGY, 2020, 30 (03) : 428 - 440

← 1 2 3 4 5 →